The telomerase-derived anticancer peptide vaccine GV1001 as an extracellular heat shock protein-mediated cell-penetrating peptide

International Journal of Molecular Sciences

Volumn 17, Issue 12, 2016, Pages

  Kim, Hong ^a   Seo, Eun Hye ^b   Lee, Seung Hyun ^b   Kim, Bum Joon ^a  

^a Seoul National University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Cell penetrating peptides (CPPs); GV1001; Heat shock protein 90; Reverse transcriptase subunit of telomerase (hTERT)

Indexed keywords

CANCER VACCINE; CELL PENETRATING PEPTIDE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PEPTIDE VACCINE; TELOMERASE; TERTOMOTIDE; PEPTIDE FRAGMENT; SUBUNIT VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELL PROTECTION; CONFOCAL MICROSCOPY; CYTOSOL; ENDOCYTOSIS; EXTRACELLULAR SPACE; FLUORESCENCE ACTIVATED CELL SORTING; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTOTOXICITY; NONHUMAN; PINOCYTOSIS; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CHEMISTRY;

ANIMALS; CELL-PENETRATING PEPTIDES; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PEPTIDE FRAGMENTS; TELOMERASE; VACCINES, SUBUNIT;

EID: 85006051859     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17122054     Document Type: Review

References (58)

1. Gupta, B.; Levchenko, T.S.; Torchilin, V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 2005, 57, 637-651.
2. Vasir, J.K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2007, 59, 718-728.
3. Gump, J.M.; Dowdy, S.F. TAT transduction: The molecular mechanism and therapeutic prospects. Trends Mol. Med. 2007, 13, 443-448.
4. Frankel, A.D.; Pabo, C.O. Cellular uptake of the TAT protein from human immunodeficiency-virus. Cell 1988, 55, 1189-1193.
5. Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157, 195-206.
6. Bechara, C.; Sagan, S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013, 587, 1693-1702.
7. Choi, Y.S.; David, A.E. Cell penetrating peptides and the mechanisms for intracellular entry. Cum Pharm. Biotechnol. 2014, 15, 192-199.
8. Middleton, G.; Silcocks, P.; Cox, T.; Valle, J.; Wadsley, J.; Propper, D.; Coxon, F.; Ross, P.; Madhusudan, Si.; Roques, T. et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic canrer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol. 2014, 15, 829-840.
9. Staff, C.; Mozaffari, F.; Frodin, J.E.; Mellstedt, H.; Liljefors, M. Telomerase (GV1001) vaccination together with gemcitabine in advCnced pancreatic cancer patients. Int. J. Oncol. 2014, 45, 1293-1303.
10. Annels, N.E.; Shaw, V.E.; Gabitass, R.F.; Billingham, L.; Corrie, P.; Eatock, M.; Valle, J.; Smith, D.; Wadsley, J.; Cunningham, D. et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol. Immunother. 2014, 63,175-183.
11. Brunsvig, P.F.; Kyte, J.A.; Kersten, C.; Sundstrom, S.; Moller, M.; Nyakas, M.; Hansen, G.L.; Gaudernack, G.; Aamdal, S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 2011, 17, 6847-6857.
12. Hunger, R.E.; Kernland Lang, K.; Markowski, C.J.; Trachsel, S.; Moller, M.; Eriksen, J.A.; Rasmussen, A.M.; Braathen, L.R.; Gaudernack, G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol. Immunother. 2011, 60,1553-1564.
13. Choi, J.; Kim, H.; Kim, Y.; Jang, M.; Jeon, J.; Hwang, Y.I.; Shon, W.J.; Song, Y.W.; Kang, J.S.; Lee, W.J. The anti-inflammatory effect of GV1001 mediated by the downregulation of ENO1-induced pro-inflammatory cytokine production. Immune Netw. 2015, 15, 291-303.
14. Koo, T.Y.; Yan, J.J.; Yang, J. Protective effect of peptide GV1001 against renal ischemia-reperfusion injury in mice. Transplant. Proc. 2014, 46, 1117-1122.
15. Nava-Parada, P.; Emens, L.A. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr. Opin. Mol. Ther. 2007, 9, 490-497.
16. Kim, B.K.; Kim, B.R.; Lee, H.J.; Lee, S.A.; Kim, B.J.; Kim, H.; Won, Y.S.; Shon, W.J.; Lee, N.R.; Inn, K.S. et al. Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1 a-VEGF signaling axis. Biomaterials 2014, 35, 2924-2933.
17. Lee, S.A.; Kim, J.; Sim, J.; Kim, S.G.; Kook, Y.H.; Park, C.G.; Kim, H.R.; Kim, B.J. A telomerase-derived peptide regulates reactive oxygen species and hepatitis C virus RNA replication in HCV-infected cells via heat shock protein 90. Biochem. Biophys. Res. Commun. 2016, 471, 156-162.
18. Kim, H.; Choi, M.-S.; Inn, K.-S.; Kim, B.J. Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner. Sci. Rep. 2016, 6, 28896-28906.
19. Lee, S.A.; Kim, B.R.; Kim, B.K.; Kim, D.W.; Shon, W.J.; Lee, N.R.; Inn, K.S.; Kim, B.J. Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine. Biomaterials 2013, 34, 7495-7505.
20. Harley, C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 2008, 8,167-179.
21. Brunsvig, P.F.; Aamdal, S.; Gjertsen, M.K.; Kvalheim, G.; Markowski-Grimsrud, C.J.; Sve, I.; Dyrhaug, M.; Trachsel, S.; Moller, M.; Eriksen, J.A. et al. Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006, 55, 1553-1564.
22. Inderberg-Suso, E.M.; Trachsel, S.; Lislerud, K.; Rasmussen, A.M.; Gaudernack, G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012, 1, 670-686.
23. Shaw, V.E.; Naisbitt, D.J.; Costello, E.; Greenhalf, W.; Park, B.K.; Neoptolemos, J.P.; Middleton, G.W. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Exp. Rev. Vaccines 2010, 9, 1007-1016.
24. Tacken, P.J.; de Vries, I.J.; Torensma, R.; Figdor, C.G. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7, 790-802.
25. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145-160.
26. Bolhassani, A.; Safaiyan, S.; Rafati, S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer 2011, 10, 3-23.
27. Fittipaldi, A.; Ferrari, A.; Zoppe, M.; Arcangeli, C.; Pellegrini, V.; Beltram, F.; Giacca, M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 2003,278, 34141-34149.
28. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997, 272, 16010-16017.
29. Huang, Y.; Jiang, Y.; Wang, H.; Wang, J.; Shin, M.C.; Byun, Y.; He, H.; Liang, Y.; Yang, V.C. Curb challenges of the “Trojan Horse” approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv. Drug Deliv. Rev. 2013, 65, 1299-1315.
30. Raagel, H.; Saalik, P.; Pooga, M. Peptide-mediated protein delivery-which pathways are penetrable? Biochim. Biophys. Acta 2010, 1798, 2240-2248.
31. Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Graslund, A. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011, 2011, 414729-414739.
32. Zorko, M.; Langel, U. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 2005, 57, 529-545.
33. Zhao, F.; Zhao, Y.; Liu, Y.; Chang, X.; Chen, C.; Zhao, Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011, 7, 1322-1337.
34. Schmidt, N.; Mishra, A.; Lai, G.H.; Wong, G.C. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010, 584, 1806-1813.
35. Xiao, G.; Gan, L.S. Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int. J. Cell Biol. 2013, 2013, 703545-703559.
36. Mayer, M.P.; Bukau, B. HSP70 chaperones: Cellular functions and molecular mechanism. Cell. Mol. Life Sci. 2005, 62, 670-684.
37. Bukau, B.; Weissman, J.; Horwich, A. Molecular chaperones and protein quality control. Cell 2006, 125, 443-451.
38. Calderwood, S.K.; Theriault, J.; Gray, P.J.; Gong, J. Cell surface receptors for molecular chaperones. Methods 2007, 43, 199-206.
39. Calderwood, S.K.; Gong, J.; Murshid, A. Extracellular HSPs: The complicated roles of extracellular HSPs in immunity. Front. Immunol. 2016, 7,159-169.
40. Tsen, F.; Bhatia, A.; O'Brien, K.; Cheng, C.F.; Chen, M.; Hay, N.; Stiles, B.; Woodley, D.T.; Li, W. Extracellular heat shock protein 90 signals through subdomain II and the NPVY motif of LRP-1 receptor to Akt1 and Akt2: A circuit essential for promoting skin ell migration in vitro and wound healing in vivo. Mol. Cell. Biol. 2013, 33, 4947-4959.
41. Perez-Vargas, J.; Romero, P.; Lopez, S.; Arias, C.F. The peptide-binding and ATPase domains of recombinant hsc70 are required to interact with rotavirus and reduce its infectivity. J. Virol. 2006, 80, 3322-3331.
42. Wang, Y.P.; Liu, F.; He, H.W.; Han, Y.X.; Peng, Z.G.; Li, B.W.; You, X.F.; Song, D.Q.; Li, Z.R.; Yu, L.Y. et al. Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. Antimicrob. Agents Chemother. 2010, 54, 2070-2077.
43. Lopez, S.; Arias, C.F. Multistep entry of rotavirus into cells: A Versaillesque dance. Trends Microbiol. 2004, 12, 271-278.
44. Ivanovic, T.; Agosto, M.A.; Chandran, K.; Nibert, M.L. A role for molecular chaperone hsc70 in reovirus outer capsid disassembly. J. Biol. Chem. 2007, 282, 12210-12219.
45. Kohno, M.; Horibe, T.; Ohara, K.; Ito, S.; Kawakami, K. The membrane-lytic peptides K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure. Chem. Biol. 2014, 21, 1522-1532.
46. Gehrmann, M.; Stangl, S.; Foulds, G.A.; Oellinger, R.; Breuninger, S.; Rad, R.; Pockley, A.G.; Multhoff, G. Tumor imaging and targeting potential of an HSP70-derived 14-mer peptide. PLoS ONE 2014, 9, e105344.
47. Den Haan, J.M.; Bevan, M.J. Antigen presentation to CD8+ T cells: Cross-priming in infectious diseases. Curr. Opin. Immunol. 2001, 13,437-441.
48. Hance, M.W.; Nolan, K.D.; Isaacs, J.S. The double-edged sword: Conserved functions of extracellular Hsp90 in wound healing and cancer. Cancers 2014, 6, 1065-1097.
49. Li, W.; Tsen, F.; Sahu, D.; Bhatia, A.; Chen, M.; Multhoff, G.; Woodley, D.T. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: Intentionally or unintentionally. Int. Rev. Cell Mol. Biol. 2013, 303, 203-235.
50. Van den Berg, A.; Dowdy, S.F. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 2011, 22, 888-893.
51. Brooks, N.A.; Pouniotis, D.S.; Tang, C.K.; Apostolopoulos, V.; Pietersz, G.A. Cell-penetrating peptides: Application in vaccine delivery. Biochim. Biophys. Acta 2010, 1805, 25-34.
52. Jiang, Y.; Li, M.; Zhang, Z.; Gong, T.; Sun, X. Cell-penetrating peptides as delivery enhancers for vaccine. Curr. Pharm. Biotechnol. 2014, 15, 256-266.
53. Gurunathan, S.; Klinman, D.M.; Seder, R.A. DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18, 927-974.
54. Liu, M.A. DNA vaccines: A review. J. Intern. Med. 2003, 253, 402-410.
55. Mann, A.; Thakur, G.; Shukla, V.; Ganguli, M. Peptides in DNA delivery: Current insights and future directions. Drug Discov. Today 2008,13, 152-160.
56. McManus, M.T.; Sharp, P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 2002, 3, 737-747.
57. Zimmermann, T.S.; Lee, A.C.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M.N.; Harborth, J.; Heyes, J.A.; Jeffs, L.B.; John, M. et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441, 111-114.
58. Juliano, R.; Alam, M.R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008, 36, 41584171.